February 10, 2017 / 12:16 PM / 6 months ago

Immunomedics in $2 bln licensing deal with Seattle Genetics

Feb 10 (Reuters) - Immunomedics Inc said it entered into a licensing deal for its cancer treatment with Seattle Genetics Inc for a potential payment of up to about $2 billion.

Immunomedics would receive $250 million in upfront cash payment, the companies said on Friday. (Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below